These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 33127459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
    Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S, Fateh R, Abdolrahimi F, Dizaji SP, Fateh A, Siadat SD.
    Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
    [Abstract] [Full Text] [Related]

  • 3. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE, Mostowska A, Świderska MK, Marcinkowski W, Stolarek I, Figlerowicz M, Jagodziński PP.
    BMC Infect Dis; 2021 Jan 22; 21(1):102. PubMed ID: 33482747
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
    Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P.
    Aliment Pharmacol Ther; 2014 Jan 22; 39(1):104-11. PubMed ID: 24205831
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y.
    PLoS One; 2015 Jan 22; 10(5):e0125400. PubMed ID: 25938236
    [Abstract] [Full Text] [Related]

  • 6. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A.
    World J Gastroenterol; 2014 Sep 28; 20(36):13146-52. PubMed ID: 25278709
    [Abstract] [Full Text] [Related]

  • 7. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A.
    J Infect Dis; 2014 Jun 01; 209(11):1700-4. PubMed ID: 24367041
    [Abstract] [Full Text] [Related]

  • 8. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
    Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, Tangkijvanich P.
    J Med Virol; 2014 Sep 01; 86(9):1482-90. PubMed ID: 24782280
    [Abstract] [Full Text] [Related]

  • 9. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S, Yousuf MH, Yousaf MI.
    World J Gastroenterol; 2017 Nov 28; 23(44):7899-7905. PubMed ID: 29209131
    [Abstract] [Full Text] [Related]

  • 10. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
    Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
    Microb Pathog; 2022 Jan 28; 162():105311. PubMed ID: 34843922
    [Abstract] [Full Text] [Related]

  • 11. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S.
    Ann Hepatol; 2018 Aug 24; 17(5):815-821. PubMed ID: 30145562
    [Abstract] [Full Text] [Related]

  • 12. Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.
    Saafan AE, Abobaker A, Abbas MS, El-Gendy A.
    J Infect Dev Ctries; 2020 Jan 31; 14(1):80-88. PubMed ID: 32088688
    [Abstract] [Full Text] [Related]

  • 13. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L.
    J Hepatol; 2015 Nov 31; 63(5):1103-10. PubMed ID: 26186989
    [Abstract] [Full Text] [Related]

  • 14. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
    Fernández-Carrillo C, Coto-Llerena M, González P, Crespo G, Mensa L, Caro-Pérez N, Gambato M, Navasa M, Forns X, Pérez-del-Pulgar S.
    J Clin Virol; 2014 Oct 31; 61(2):282-5. PubMed ID: 25130512
    [Abstract] [Full Text] [Related]

  • 15. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
    Mohamed Abdelnajid D, Elmowafy AY, Rostaing L, Elrakaiby MT.
    Medicine (Baltimore); 2023 Jul 14; 102(28):e34125. PubMed ID: 37443472
    [Abstract] [Full Text] [Related]

  • 16. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y.
    J Viral Hepat; 2014 Jun 14; 21(6):397-404. PubMed ID: 24750545
    [Abstract] [Full Text] [Related]

  • 17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.
    World J Gastroenterol; 2015 Apr 07; 21(13):3904-11. PubMed ID: 25852275
    [Abstract] [Full Text] [Related]

  • 18. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, Nguyen T, Iser DM, Visvanathan K, Sievert W, Bowden DS, Desmond PV, Thompson AJ.
    Aliment Pharmacol Ther; 2015 Aug 07; 42(3):296-306. PubMed ID: 26032235
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S, Proske V, Otto B, Pischke S, Costa R, Lüthgehetmann M, Polywka S, Klempnauer J, Nashan B, Manns MP, von Hahn T, Lohse AW, Wedemeyer H, Mix H, Sterneck M.
    Transpl Infect Dis; 2016 Jun 07; 18(3):326-32. PubMed ID: 26988272
    [Abstract] [Full Text] [Related]

  • 20. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L, Di Biagio A, Sartini M, Rappazzo E, Nicolini LA, Cenderello G, Valle C, Azzola E, Grasso A, De Leo P, Boldrini A, Setti M, Prinapori R, Lorusso C, Bruzzone B, Icardi G, Ligurian HIV Network.
    New Microbiol; 2015 Oct 07; 38(4):499-509. PubMed ID: 26485009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.